The Oncologist: Patient Conversation Must Include Clinical Trials


Dr. Shalaan Beg, VP of Oncology for Science 37, discusses his approach to reducing the time to trial activation at an NCI designated cancer center, how to ensure a diverse representation in clinical trials, and his opinion on decentralized and hybrid trials.

This podcast sponosored by LabVantage Soultions

© 2024 MJH Life Sciences

All rights reserved.